HROW Stock: Price, Earnings History and SEC Filings
Harrow, Inc. (HROW) last traded at $28.24, down 5.84% on the latest session and down 8.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.34 against an analyst estimate of $-0.23, a miss of 47.8%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
HROW earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.34 | $-0.23 | -47.83% |
| Mar 2026 | May 11, 2026 | $-0.63 | $-0.43 | -46.51% |
| Dec 2025 | Mar 2, 2026 | $0.26 | $0.40 | -35.00% |
| Sep 2025 | Nov 10, 2025 | $0.33 | $0.22 | +50.00% |
HROW beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How HROW reacts to earnings
Across its last 8 earnings releases, HROW moved 11.3% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-10 | After close | -3.14% |
| 2026-05-11 | After close | -23.69% |
| 2026-03-02 | After close | -27.95% |
| 2026-02-02 | Before open | +9.67% |
| 2025-11-10 | After close | +13.47% |
| 2025-08-11 | After close | +3.23% |
| 2025-05-08 | After close | +3.43% |
| 2025-03-27 | After close | -5.96% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
HROW financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $272M | -$5M | $43M | -1.9% | $-0.14 |
| 2024 | $200M | -$17M | -$24M | -8.8% | $-0.49 |
| 2023 | $130M | -$24M | $2M | -18.7% | $-0.75 |
| 2022 | $89M | -$14M | -$892000 | -15.9% | $-0.51 |
| 2021 | $72M | -$18M | $3M | -24.8% | – |
| 2020 | $49M | -$3M | -$2M | -6.9% | $-0.13 |
| 2019 | $51M | $168000 | -$518000 | 0.3% | $0.01 |
| 2018 | $41M | $15M | -$1M | 35.3% | $0.61 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for HROW
- 8-K · Oct 5, 2026Material agreement, Acquisition or disposal completed, Regulation FD disclosure
- 8-K · Sep 4, 2026Officer or director change, Financial statements and exhibits
- 10-Q · Aug 10, 2026
- 8-K · Aug 10, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 6, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 22, 2026Shareholder vote
- 8-K · Jun 3, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · May 11, 2026
- 8-K · May 11, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- DEF 14A · Apr 24, 2026
Insider filing activity
HROW insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
HROW news
- Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026Oct 26, 2026 · finance.yahoo.com
About Harrow, Inc.
Harrow, Inc. (HROW) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.